Audentes Therapeutics, Inc.
From Verify.Wiki
 | |
| | |
| Audentes Therapeutics, Inc. | |
|---|---|
| Type | Public |
| Industry | Biotechnology |
| Founded | 2012 |
| Headquarters | San Francisco, CA, United States |
| Key people | Matthew R. Patterson (CEO), Suyash Prasad (Chief Medical Officer), John T. Gray [1] |
| Investors | 5AM Ventures, Cormorant Asset Management, Deerfield, Foresite Capital, OrbiMed, RA Capital Management, Redmile Group, Rock Springs, Capital, Sofinnova Ventures, T. Rowe Price, Venrock, Versant Ventures [2] |
| Number of employees | 76 [3] |
Audentes Therapeutics, Inc., a biotechnology company focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects in the United States.
They follow that the gene therapy has powerful potential to treat these diseases through delivery of a functional copyof the affected gene to cells, resulting in production of the normal protein. [4]
Contents
Products
The products include :
- AT132 for the treatment of X-Linked Myotubular Myopathy
- XLMTM, AT342 for the treatment of Crigler-Najjar Syndrome
- Crigler-Najjar, AT982 for the treatment of Pompe disease
- AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia
- CASQ2-CPVT. We plan to submit Investigational New Drug applications
- INDs, or Clinical Trial Authorisations, or CTAs, for AT982 in the third quarter of 2016
They maintain full global rights to all of our product candidates. [5]
Controversies
None Reported
Top 5 Recent Tweets
| Date | Author | Comment |
|---|---|---|
| October 31, 2022 | IncredibleTrade | $TSHA Form SC 13D Taysha Gene Therapies, Filed by: Audentes Therapeutics, Inc. @Street_Insider |
| October 31, 2022 | FlashAlert_me | $TSHA [15s. delayed] filed SEC form 3: 10% Owner Audentes Therapeutics, Inc.: https://t.co/EXmhSoWqZc |
Top 5 Recent News Headlines
Top 5 Lifetime Tweets
Top 5 Lifetime News Headlines
- ↑ http://audentestx.com/company/
- ↑ https://www.crunchbase.com/organization/audentes-therapeutics#/entity
- ↑ http://www.nasdaq.com/markets/ipos/company/audentes-therapeutics-inc-953394-80103
- ↑ http://www.nasdaq.com/markets/ipos/company/audentes-therapeutics-inc-953394-80103#ixzz4ReMztNy0
- ↑ http://www.nasdaq.com/markets/ipos/company/audentes-therapeutics-inc-953394-80103#ixzz4ReNKF47T
Top Authors
Verification history
2,914 days ago- View all verifications
